Frederick Moody
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Frederick Moody has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Patrick Ashinze
Faculty of Clinical Sciences, University of Ilorin, Ilorin 240003, Nigeria
2 shared publications - Abdulgafar Yusuf1 shared publication
- Adeshina Abdulbasit Ahmed1 shared publication
- Babas Puamus Oki
I. Horbachevsky Ternopil National Medical University
1 shared publication - Hussein Bello
Faculty of Clinical Sciences, University of Ilorin, Ilorin 240003, Nigeria
1 shared publication - Nwoke Obinna Chidubem
Department of Pharmacology and Therapeutics, Faculty of Basic Clinical Sciences, College of Medicine, University of Nigeria, Nsukka 410001, Nigeria
1 shared publication
Latest Publications
- Open Access
- 4 November 2026
- Published by Open Exploration Publishing in Exploration of Cardiology
- Vol. 4, 1012128
Theranostic advances in cardio-oncology: integrating precision diagnostics and targeted therapies for cardiovascular protection in cancer patients
Cardio-oncology has emerged as a critical interdisciplinary field addressing the growing burden of cardiovascular complications arising from modern cancer therapies. While advances in chemotherapy, targeted agents, and immunotherapies have substantially improved cancer survival, they have concurrently led to a significant rise in cancer therapy-related cardiac dysfunction (CTRCD), contributing to increased long-term morbidity and mortality among cancer survivors. Conventional surveillance strategies often detect cardiotoxicity only after irreversible myocardial injury has occurred, accentuating the need for more precise, proactive, and personalized approaches. Theranostics, integrating diagnostic imaging, molecular biomarkers, and targeted therapeutics, offers a promising paradigm to enable early detection, risk stratification, and tailored cardioprotective interventions in cardio-oncology. This review synthesizes recent advances in theranostic strategies relevant to cardio-oncology, spanning imaging-based, biomarker-driven, and nanotechnology-enabled approaches. Advanced imaging modalities such as hybrid PET/MRI, AI-enhanced echocardiography, and novel molecular radiotracers [e.g., 68Ga-FAPI, 18F-DHMT, [68Ga]pentixafor] enable early identification of subclinical myocardial injury, inflammation, fibrosis, and metabolic dysfunction before overt declines in left ventricular ejection fraction occur. Complementing imaging, biomarker-driven theranostics including high-sensitivity cardiac troponins, natriuretic peptides, circulating and exosomal microRNAs, and cardiomyocyte-specific cell-free DNA, provide minimally invasive, real-time insights into myocardial stress, injury, and immune-mediated cardiotoxicity. Nanotheranostic platforms, such as liposomal doxorubicin and immunomodulatory nanoparticles, further enhance therapeutic precision by reducing off-target cardiac exposure while preserving antitumor efficacy. Despite these advances, clinical translation remains hindered by interdisciplinary fragmentation, limited access to advanced infrastructure, high development costs, regulatory heterogeneity between agencies, and reliance on surrogate endpoints rather than long-term cardiovascular outcomes. Theranostics represents a transformative approach in cardio-oncology. Integration of advanced imaging, molecular biomarkers, artificial intelligence, and nanotechnology holds significant promise for preserving cardiac health without compromising oncologic success. Embedding theranostic strategies into routine cardio-oncology practice is essential to advancing precision medicine and improving cardiovascular outcomes for cancer patients worldwide.
- 4 November 2026
- Published by Open Exploration Publishing in Exploration of Cardiology
- Vol. 4, 1012128
Open AccessTheranostic advances in cardio-oncology: integrating precision diagnostics and targeted therapies for cardiovascular protection in cancer patients
Cardio-oncology has emerged as a critical interdisciplinary field addressing the growing burden of cardiovascular complications arising from modern cancer therapies. While advances in chemotherapy, targeted agents, and immunotherapies have substantially improved cancer survival, they have concurrently led to a significant rise in cancer therapy-related cardiac dysfunction (CTRCD), contributing to increased long-term morbidity and mortality among cancer survivors. Conventional surveillance strategies often detect cardiotoxicity only after irreversible myocardial injury has occurred, accentuating the need for more precise, proactive, and personalized approaches. Theranostics, integrating diagnostic imaging, molecular biomarkers, and targeted therapeutics, offers a promising paradigm to enable early detection, risk stratification, and tailored cardioprotective interventions in cardio-oncology. This review synthesizes recent advances in theranostic strategies relevant to cardio-oncology, spanning imaging-based, biomarker-driven, and nanotechnology-enabled approaches. Advanced imaging modalities such as hybrid PET/MRI, AI-enhanced echocardiography, and novel molecular radiotracers [e.g., 68Ga-FAPI, 18F-DHMT, [68Ga]pentixafor] enable early identification of subclinical myocardial injury, inflammation, fibrosis, and metabolic dysfunction before overt declines in left ventricular ejection fraction occur. Complementing imaging, biomarker-driven theranostics including high-sensitivity cardiac troponins, natriuretic peptides, circulating and exosomal microRNAs, and cardiomyocyte-specific cell-free DNA, provide minimally invasive, real-time insights into myocardial stress, injury, and immune-mediated cardiotoxicity. Nanotheranostic platforms, such as liposomal doxorubicin and immunomodulatory nanoparticles, further enhance therapeutic precision by reducing off-target cardiac exposure while preserving antitumor efficacy. Despite these advances, clinical translation remains hindered by interdisciplinary fragmentation, limited access to advanced infrastructure, high development costs, regulatory heterogeneity between agencies, and reliance on surrogate endpoints rather than long-term cardiovascular outcomes. Theranostics represents a transformative approach in cardio-oncology. Integration of advanced imaging, molecular biomarkers, artificial intelligence, and nanotechnology holds significant promise for preserving cardiac health without compromising oncologic success. Embedding theranostic strategies into routine cardio-oncology practice is essential to advancing precision medicine and improving cardiovascular outcomes for cancer patients worldwide.
- Open Access
- 28 June 2025
- Published by MediHealth Academy in Academic Journal of Neurology and Neurosurgery
- Vol. 2 (2) , 41-43
Neurobiobanking in Africa: accelerating stroke care equity, curation and research - a functional approach
Neurobiobanking—the systematic collection, processing, and storage of central nervous system (CNS) tissues and associated data—holds immense promise for elucidating the genetic, molecular, and environmental determinants of stroke. In Africa, where stroke incidence is rising, age of onset is younger, and outcomes are poorer than in high-income settings, region-specific neurobiologic repositories can drive equitable research and tailored interventions. Despite significant advances through precision healthcare initiatives like H3Africa and the National Health Laboratory Service (NHLS) National Biobank, most countries still grapple with funding shortfalls, infrastructure gaps, trained personnel inadequacy and schismic regulatory frameworks. This focused communication outlines the current visage of neurobiobanking in Africa, showcases its critical role in addressing the continent’s huge stroke burden, and proposes actionable strategies to establish inclusive, ethically governed, and sustainable neurobiobank networks.
- 28 June 2025
- Published by MediHealth Academy in Academic Journal of Neurology and Neurosurgery
- Vol. 2 (2) , 41-43
Open AccessNeurobiobanking in Africa: accelerating stroke care equity, curation and research - a functional approach
Neurobiobanking—the systematic collection, processing, and storage of central nervous system (CNS) tissues and associated data—holds immense promise for elucidating the genetic, molecular, and environmental determinants of stroke. In Africa, where stroke incidence is rising, age of onset is younger, and outcomes are poorer than in high-income settings, region-specific neurobiologic repositories can drive equitable research and tailored interventions. Despite significant advances through precision healthcare initiatives like H3Africa and the National Health Laboratory Service (NHLS) National Biobank, most countries still grapple with funding shortfalls, infrastructure gaps, trained personnel inadequacy and schismic regulatory frameworks. This focused communication outlines the current visage of neurobiobanking in Africa, showcases its critical role in addressing the continent’s huge stroke burden, and proposes actionable strategies to establish inclusive, ethically governed, and sustainable neurobiobank networks.